SCHEDULE 13G: Aberdeen Group Discloses 8.88% Stake in Precision Bio
Beneficial Ownership Disclosure
Aberdeen Group plc and abrdn Inc. have reported a shared beneficial ownership of 8.88% in Precision Biosciences Inc. as of December 31, 2025.
Summary
- Aberdeen Group plc and its subsidiary abrdn Inc. jointly reported beneficial ownership of 2,138,603 shares of Precision Biosciences Inc. common stock.
- This ownership represents 8.88% of the company's outstanding common stock.
- The event requiring this filing occurred on December 31, 2025.
- Both reporting entities hold shared voting power and shared dispositive power over all 2,138,603 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of beneficial ownership. The presence of a significant institutional investor (8.88%) can be interpreted as a moderately positive signal of confidence in the company, hence a slightly positive score.
Positives
- A significant institutional investment from Aberdeen Group plc and abrdn Inc. may signal confidence in Precision Biosciences Inc.'s long-term prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Precision Biosciences Inc.'s future performance or strategic direction, beyond the beneficial ownership as of the specified date.
Industry Context
Institutional investment in biotechnology companies like Precision Biosciences Inc. is common, reflecting investor interest in the sector's growth potential and innovative developments. A significant stake by a major asset manager like abrdn can be viewed as a positive indicator within the industry.
Stakeholder Impact
- Shareholders may view the significant institutional stake by Aberdeen Group and abrdn Inc. as a positive sign, potentially increasing investor confidence and market stability for Precision Biosciences Inc.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires the filing of this statement, indicating the beneficial ownership percentage. |
| 01/16/2026 | Signature date of the Schedule 13G filing by Aberdeen Group plc and abrdn Inc. |
Keywords
Precision Biosciences, Aberdeen Group, abrdn, beneficial ownership, Schedule 13G, institutional investment, common stock, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.